1 MIN. DE LECTURA
Feb 12 (Reuters) - Thrombogenics NV :
* Announces that Jetrea (Ocriplasmin) has gained approval in Argentina and Israel
* Thrombogenics' partner Alcon, which is commercializing Jetrea outside the US, will be responsible for the launch of the drug in Argentina and Israel.
* Jetrea has been indicated for the treatment of adults with vitreomacular traction (VMT) Source text: (bit.ly/1ApXAOF) Further company coverage: (Bengaluru Newsroom; +44 207 542 1810)